1. Home
  2. VRDN vs DBD Comparison

VRDN vs DBD Comparison

Compare VRDN & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • DBD
  • Stock Information
  • Founded
  • VRDN 2006
  • DBD 1859
  • Country
  • VRDN United States
  • DBD United States
  • Employees
  • VRDN N/A
  • DBD N/A
  • Industry
  • VRDN Medical Specialities
  • DBD EDP Services
  • Sector
  • VRDN Health Care
  • DBD Technology
  • Exchange
  • VRDN Nasdaq
  • DBD Nasdaq
  • Market Cap
  • VRDN 1.5B
  • DBD 1.8B
  • IPO Year
  • VRDN N/A
  • DBD N/A
  • Fundamental
  • Price
  • VRDN $20.14
  • DBD $40.27
  • Analyst Decision
  • VRDN Strong Buy
  • DBD Strong Buy
  • Analyst Count
  • VRDN 10
  • DBD 2
  • Target Price
  • VRDN $37.25
  • DBD $57.50
  • AVG Volume (30 Days)
  • VRDN 1.1M
  • DBD 255.4K
  • Earning Date
  • VRDN 11-12-2024
  • DBD 11-07-2024
  • Dividend Yield
  • VRDN N/A
  • DBD N/A
  • EPS Growth
  • VRDN N/A
  • DBD N/A
  • EPS
  • VRDN N/A
  • DBD 0.00
  • Revenue
  • VRDN $302,000.00
  • DBD $3,799,000,000.00
  • Revenue This Year
  • VRDN N/A
  • DBD $0.86
  • Revenue Next Year
  • VRDN N/A
  • DBD $1.19
  • P/E Ratio
  • VRDN N/A
  • DBD $7,622.28
  • Revenue Growth
  • VRDN N/A
  • DBD 2.88
  • 52 Week Low
  • VRDN $11.40
  • DBD $22.74
  • 52 Week High
  • VRDN $27.20
  • DBD $51.81
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 36.38
  • DBD 34.53
  • Support Level
  • VRDN $22.40
  • DBD $38.50
  • Resistance Level
  • VRDN $27.20
  • DBD $42.00
  • Average True Range (ATR)
  • VRDN 1.36
  • DBD 2.10
  • MACD
  • VRDN -0.41
  • DBD -0.94
  • Stochastic Oscillator
  • VRDN 6.37
  • DBD 8.72

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

About DBD Diebold Nixdorf Incorporated Common stock

Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.

Share on Social Networks: